featured
news articles

Total number of categories

Total number of articles

Market/Novel Tech

Spark Therapeutics announces plans to have 10 gene therapy clinical programs in place by 2018, including up to three ophthalmic indications

Spark Therapeutics (NASDAQ:ONCE), a gene therapy company based in Philadelphia, USA, has announced a three year vision to expand the company’s gene therapy portfolio and launch its first commercial product in 2017. The company’s lead gene therapy product, termed “SPK-RPE65”, is a replacement gene therapy treatment for RPE65-mediated inherited retinal degeneration. Spark had previously announced […]

Read full story
Featured

Phase II clinical trial results for micro-injection of triamcinolone in treatment of macular edema (following non-infectious uveitis) reaches primary endpoint

Results from a Phase II study to evaluate the safety and efficacy of a micro- injectable formulation of triamcinolone for the treatment of macular edema (associated with non-infectious uveitis) has reported a statistically significant mean change from baseline in central subfield thickness at eight weeks following a single administration of the drug (p=0.0018). The sponsior […]

Read full story
Research

Genomic meta-analysis across patient DNA of European ancestry uncovers three additional genetic loci behind glaucoma

Research conducted by an international consortium of ophthalmic genetic specialists has reported the identification of a further three loci believed to contribute to the pathology of primary open angle glaucoma. In a significant publication in the journal Nature Genetics, the researchers reported the results of a meta-analysis on the genome-wide association study results of eight […]

Read full story
Introduction

January 18th, 2016: “EURETINA-Brief”© Issue No. 125

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the January 18th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story
Featured

CRISPR gene editing technology continues to create significant commercial interest including applications to ophthalmology

The recently developed CRISPR gene editing technology is currently generating significant interest in the biomedical community, not least of all due to its low cost, its incredible ease of use and its versatility across a broad range of applications (see Bayer-CRISPR Therapeutics joint venture announcement in this issue). Referred to as “clustered regularly interspaced short […]

Read full story
Market/Novel Tech

AGTC Inc receives US FDA orphan designation of experimental gene therapy treatment for achromatopsia

Applied Genetic Technologies Corp. (NASDAQ: AGTC), a gene therapy company based in Gainesville, Florida, has announced the receipt of orphan drug designation from the U.S. Food and Drug Administration (FDA) for its gene therapy product candidate to treat achromatopsia, a disorder arising from mutations in the CNGA3 gene. AGTC is developing products for achromatopsia based […]

Read full story

Latest News

Book Review